NewsBenzinga크리스퍼 테라퓨틱스, 유전자 편집 치료제 임상 시험에서 상당한 지질 감소 효과 확인 크리스퍼 테라퓨틱스, 유전자 편집 치료제 임상 시험에서 상당한 지질 감소 효과 확인 Benzinga 2026.11.10 18:48 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report